CyberKnife radiosurgery delivers the precision of surgery without a single incision. Using a robotic arm and hundreds of finely focused radiation beams, it destroys tumors deep inside the body in just one to five outpatient sessions — no scalpel, no general anaesthesia, and usually no hospital stay. Here is how it works, what it treats, and how patients can access it through Medical E-Aid.

What is CyberKnife?

CyberKnife is a stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) system built by Accuray. Despite the name, there is no knife and no cutting. A compact linear accelerator mounted on a robotic arm fires many small, precisely aimed beams of radiation that converge on the tumor. Where the beams meet, the combined dose is high enough to destroy cancer cells; the surrounding healthy tissue receives only a fraction of that dose.

Unlike the Gamma Knife — which treats only tumors inside the skull — CyberKnife can treat tumors almost anywhere in the body, both intracranial and extracranial.

How CyberKnife works

Three features make the treatment exceptionally precise:

• Image guidance: the system takes live X-ray images during treatment to confirm the exact position of the tumor.
• Real-time motion tracking: for tumors that move when you breathe — in the lung, liver or prostate — CyberKnife tracks that movement and adjusts the beam continuously, so the target stays locked even as the body moves.
• Robotic delivery: the robotic arm moves around the patient to aim beams from hundreds of different angles, shaping the dose tightly to the tumor with sub-millimetre accuracy.

Each session typically takes about 30 minutes to two hours, and most courses are complete in one to five sessions.

What conditions does CyberKnife treat?

CyberKnife is used for both cancerous and benign conditions, including:

• Brain tumors and metastases that are hard to reach with conventional surgery
• Acoustic neuroma and other skull-base tumors
• Trigeminal neuralgia
• Spinal and spinal-cord tumors
• Lung tumors and lung metastases — including in patients who cannot undergo surgery
• Prostate cancer
• Pancreatic and liver tumors
• Recurrent tumors previously treated with other methods

CyberKnife for prostate cancer

Prostate cancer is one of the most established uses of CyberKnife SBRT. The entire course is usually condensed into about five sessions over one to two weeks, compared with 40–45 sessions over roughly nine weeks for conventional radiation. In published studies, five-year disease-control rates have been high — frequently in the range of 97–100% for low-risk and 88–97% for intermediate-risk disease — with side-effect profiles comparable to standard external-beam radiotherapy and quality of life typically returning to baseline within months. Because it is non-invasive, CyberKnife avoids the incisions of surgery and the implants of brachytherapy.

The benefits at a glance

• Non-invasive — no incision, no implants, no general anaesthesia
• Fast — typically 1–5 sessions instead of weeks of daily radiation
• Outpatient — most patients go home the same day and resume normal activity quickly
• Organ-preserving — high precision spares surrounding healthy tissue
• An option when surgery isn’t — suitable for many medically inoperable or recurrent cases

What to expect

Treatment begins with imaging (CT, and often MRI or PET-CT) and a personalised plan created by a radiation-oncology team. During each session you simply lie still while the robotic arm moves around you — there is no pain and no recovery room. Because there is no surgery, there is no wound to heal, and side effects are usually mild and temporary.

Accessing CyberKnife with Medical E-Aid

CyberKnife is available only at specialised radiosurgery centres. Medical E-Aid connects patients with leading, internationally equipped centres — including one of the highest-volume radiosurgery networks in the region — and coordinates the whole journey: a medical review of your case, a treatment plan and cost estimate, and full support with travel, visas, interpretation and aftercare. Our AI pre-screening helps match your specific condition to the right specialist and clinic, often at a fraction of Western-market cost.

This article is for general information only and is not medical advice. Treatment suitability depends on each patient’s diagnosis and must be determined by qualified specialists. Outcome figures are drawn from published clinical studies and may not reflect individual results.

Sources: MedlinePlus (U.S. National Library of Medicine); Accuray; CyPro Trial, Frontiers in Oncology (2023).